Literature DB >> 27552557

US-guided Microwave Ablation of Hyperplastic Parathyroid Glands: Safety and Efficacy in Patients with End-Stage Renal Disease-A Pilot Study.

Li Zhuo1, Li-Li Peng1, Yu-Mei Zhang1, Zhi-Hong Xu1, Gu-Ming Zou1, Xin Wang1, Wen-Ge Li1, Ming-de Lu1, Ming-An Yu1.   

Abstract

Purpose To evaluate the safety and efficacy of microwave ablation (MWA) in patients with end-stage renal disease and secondary hyperparathyroidism. Materials and Methods The study protocol was approved by the human ethics review committee. Between March 1, 2014, and June 30, 2015, 51 patients (25 men, 26 women; mean age ± standard deviation, 53.1 years ± 12.9) were enrolled. All patients had at least one enlarged parathyroid gland and secondary symptomatic hyperparathyroidism, which was treated with ultrasonographically (US) guided MWA. The levels of intact parathyroid hormone, serum calcium, phosphorus, and alkaline phosphatase were compared before and after MWA. Paired-sample t tests and paired-sample Wilcoxon signed-rank tests were used to compare treatment outcomes before and after MWA. Results Complete ablation was achieved in all 96 glands in 51 of 120 patients with severe secondary hyperparathyroidism. The mean follow-up time was 11.1 months ± 3.3. The maximum diameter of the glands ranged from 0.5 cm to 4.8 cm (mean, 1.5 cm ± 0.6). The ablation time for each gland was 216.1 seconds ± 130.1. The mean serum intact parathyroid hormone, calcium, and phosphorus levels after MWA (400 pg/mL [400 ng/L; range, 151.3-629.0 ng/L], 2.33 mmol/L ± 0.23, and 1.54 mmol/L ± 0.43, respectively) were significantly lower than those before MWA (1203 pg/mL [1203 ng/L; range, 854.7-1694.5 ng/L], 2.53 mmol/L ± 0.24, and 1.97 mmol/L ± 0.50, respectively; P < .01), while the alkaline phosphatase levels did not change with MWA (P > .05). Ipsilateral recurrent laryngeal nerve injury was seen in one patient (2%). A hematoma developed during one procedure in one patient (2%) and was treated successfully with injection of thrombin. Conclusion US-guided MWA is safe and effective for destroying parathyroid gland tissue in patients with end-stage renal disease and severe secondary hyperparathyroidism. Further experience with the technique is clearly necessary. © RSNA, 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27552557     DOI: 10.1148/radiol.2016151875

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

1.  Pseudoaneurysm of superior thyroid artery following ultrasound-guided radiofrequency ablation of hyperplastic parathyroid gland: a case report and literature review.

Authors:  Shuyuan Tian; Guo Tian; Tianan Jiang
Journal:  Quant Imaging Med Surg       Date:  2020-05

2.  Comparison of microwave ablation treatments in patients with renal secondary and primary hyperparathyroidism.

Authors:  Haoyang Ma; Chun Ouyang; Yaoyu Huang; Changying Xing; Chen Cheng; Wei Liu; Donglan Yuan; Ming Zeng; Xiangbao Yu; Haibin Ren; Yanggang Yuan; Lina Zhang; Fangyan Xu; Ying Cui; Wenkai Ren; Hui Huang; Hanyang Qian; Boqiang Fan; Ningning Wang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

3.  Efficacy of Ultrasound-guided Radiofrequency Ablation of Parathyroid Hyperplasia: Single Session vs. Two-Session for Effect on Hypocalcemia.

Authors:  Zeng Zeng; Cheng-Zhong Peng; Ji-Bin Liu; Yi-Wen Li; Hong-Feng He; Qiao-Hong Hu; Bo Lin; Xiao-Gang Shen
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

4.  Clinical Study on Safety and Efficacy of Microwave Ablation for Primary Hyperparathyroidism.

Authors:  Ying Wei; Lili Peng; Yan Li; Zhen Long Zhao; Ming An Yu
Journal:  Korean J Radiol       Date:  2020-05       Impact factor: 3.500

5.  Value of contrast-enhanced ultrasonography in radiofrequency ablation of secondary hyperparathyroidism.

Authors:  Xiachuan Qin; Baofu Wang; Boliang Li; Changwei Lin; Xuebin Liu; Xisheng Xie
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

6.  Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Primary Hyperparathyroidism: A Prospective Study.

Authors:  Hui-Hui Chai; Yu Zhao; Zeng Zeng; Rui-Zhong Ye; Qiao-Hong Hu; Hong-Feng He; Jung Hwan Baek; Cheng-Zhong Peng
Journal:  Korean J Radiol       Date:  2022-05       Impact factor: 7.109

7.  Severe secondary hyperparathyroidism in a chronic kidney disease patient treated with Radiofrequency ablation: One case report.

Authors:  Gulimire Muhetaer; Guangyi Liu; Ling Zhang; Hong Jiang
Journal:  Front Med (Lausanne)       Date:  2022-07-22

8.  Evaluation of efficacy of ultrasound-guided microwave ablation in primary hyperparathyroidism.

Authors:  Mingzhu Zhang; Yuxiu Gao; Xiaojuan Zhang; Zhaoyan Ding; Xinya Wang; Wenbin Jiang; Cheng Zhao
Journal:  J Clin Ultrasound       Date:  2022-01-05       Impact factor: 0.869

9.  Minimally Invasive Treatment for Benign Parathyroid Lesions: Treatment Efficacy and Safety Based on Nodule Characteristics.

Authors:  Eun Ju Ha; Jung Hwan Baek; Sun Mi Baek
Journal:  Korean J Radiol       Date:  2020-08-04       Impact factor: 3.500

10.  A study on the causes of operative failures after microwave ablation for primary hyperparathyroidism.

Authors:  Wei Ying; Zhao Zhen-Long; Cao Xiao-Jing; Peng Li-Li; Li Yan; Yu Ming-An
Journal:  Eur Radiol       Date:  2021-03-02       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.